Osteopontin predicts long-term functional outcome among ischemic stroke patients

Journal of Neurology

Volumn 258, Issue 3, 2011, Pages 486-493

  Mendioroz, M ^a   Fernandez Cadenas I ^a   Rosell, A ^a   Delgado, P ^a   Domingues Montanari, S ^a   Ribo M ^a   Penalba, A ^a   Quintana, M ^a   Alvarez Sabin J ^a   Montaner, J ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Biomarker; Ischemic stroke; OPN; Osteopontin; Prognosis; Stroke

Indexed keywords

OSTEOPONTIN; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTICLE; BRAIN ISCHEMIA; CONTINUOUS INFUSION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBRINOLYTIC THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANKIN SCALE; STROKE PATIENT;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BRAIN ISCHEMIA; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; OSTEOPONTIN; PREDICTIVE VALUE OF TESTS; RECOVERY OF FUNCTION; STROKE; TIME FACTORS; TREATMENT OUTCOME;

EID: 79953770665     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-010-5785-z     Document Type: Article

References (31)

1. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE (1993) Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in acute stroke treatment. Stroke 24:35-41
2. Agnihotri R, Crawford HC, Haro H, Matrisian LM, Havrda MC, Liaw L (2001) Osteopontin, a novel substrate for matrix metalloproteinase-3 (stromelysin-1) and matrix metalloproteinase- 7 (matrilysin). J Biol Chem 276:28261-28267
3. Asplund K, Stegmayr B, Peltonen M (1998) From the twentieth to the twenty-first century: a public health perspective on stroke. In: Ginsberg MD, Bogousslavsky J (eds) Cerebrovascular disease pathophysiology, diagnosis, and management, Chap 64, vol 2. Blackwell Science, Malden
4. Bamford J, Sandercock P, Dennis M, Burn J, Warlow C (1991) Classification and natural history of clinical subtypes of cerebral infarction. Lancet 337:1521-1526
5. Brott TG, Haley EC Jr, Levy DE, Barsan W, Broderick J, Sheppard GL, Spilker J, Kongable GL, Massey S, Reed R (1992) Urgent therapy for stroke. Part I. Pilot study of tissue plasminogen activator administered within 90 minutes. Stroke 23:632-640
6. Brott T, Bogousslavsky J (2000) Treatment of acute ischemic stroke. N Engl J Med 343:710-722
7. Centers for Disease Control, Prevention (CDC) (2002) Prevalence of disabilities and associated health conditions among adults: United States, 1999. MMWR Morb Mortal Wkly Rep 50:120-125
8. de Kleijn DP, Moll FL, Hellings WE, Ozsarlak-Sozer G, de Bruin P, Doevendans PA, Vink A, Catanzariti LM, Schoneveld AH, Algra A, Daemen MJ, Biessen EA, de Jager W, Zhang H, de Vries JP, Falk E, Lim SK, van der Spek PJ, Sze SK, Pasterkamp G (2010) Local atherosclerotic plaques are a source of prognostic biomarkers for adverse cardiovascular events. Arterioscler Thromb Vasc Biol 30:612-619
9. Demchuk AM, Burgin WS, Christou I, Felberg RA, Barber PA, Hill MD, Alexandrov AV (2001) Thrombolysis in brain ischemia (TIBI) transcranial Doppler flow grades predict clinical severity, early recovery, and mortality in patients treated with intravenous tissue plasminogen activator. Stroke 32:89-93 (Pubitemid 32063829)
10. Doyle KP, Yang T, Lessov NS, Ciesielski TM, Stevens SL, Simon RP, King JS, Stenzel-Poore MP (2008) Nasal administration of osteopontin peptide mimetics confers neuroprotection in stroke. J Cereb Blood Flow Metab 28:1235-1248 (Pubitemid 351733347)
11. Elkind MS, Tai W, Coates K, Paik MC, Sacco RL (2006) High-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke. Arch Intern Med 166:2073-2080 (Pubitemid 44631394)
12. Ellison JA, Velier JJ, Spera P, Jonak ZL, Wang X, Barone FC, Feuerstein GZ (1998) Osteopontin and its integrin receptor alpha(v) beta3 are upregulated during formation of the glial scar after focal stroke. Stroke 29:1698-1706
13. Gao YA, Agnihotri R, Vary CP, Liaw L (2004) Expression and characterization of recombinant osteopontin peptides representing matrix metalloproteinase proteolytic fragments. Matrix Biol 23:457-466 (Pubitemid 39576660)
14. Giachelli CM, Bae N, Almeida M, Denhardt DT, Alpers CE, Schwartz SM (1993) Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques. J Clin Invest 92:1686-1696 (Pubitemid 23304531)
15. Giachelli CM, Lombardi D, Johnson RJ, Murry CE, Almeida M (1998) Evidence for a role of osteopontin in macrophage infiltration in response to pathological stimuli in vivo. Am J Pathol 152:353-358 (Pubitemid 28106380)
16. Giachelli CM, Speer MY, Li X, Rajachar RM, Yang H (2005) Regulation of vascular calcification: roles of phosphate and osteopontin. Circ Res 96:717-722 (Pubitemid 40559510)
17. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, Boysen G, Bluhmki E, Höxter G, Mahagne MH (1995) Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: the European cooperative acute stroke study (ECASS). JAMA 274:1017-1025
18. Iwanaga Y, Ueno M, Ueki M, Huang CL, Tomita S, Okamoto Y, Ogawa T, Ueda N, Maekawa N, Sakamoto H (2008) The expression of osteopontin is increased in vessels with blood-brain barrier impairment. Neuropathol Appl Neurobiol 34:145-154 (Pubitemid 351327956)
19. Kato R, Momiyama Y, Ohmori R, Tanaka N, Taniguchi H, Arakawa K, Nakamura H, Ohsuzu F (2009) Prognostic significance of plasma osteopontin levels in patients undergoing percutaneous coronary intervention. Circ J 73:152-157
20. Lip GY, Patel JV, Hughes E, Hart RG (2007) High-sensitivity C-reactive protein and soluble CD40 ligand as indices of inflammation and platelet activation in 880 patients with nonvalvular atrial fibrillation: relationship to stroke risk factors, stroke risk stratification schema, and prognosis. Stroke 38:1229-1237 (Pubitemid 351664238)
21. Lloyd-Jones D, Adams R, Carnethon M et al (2009) American Heart Association Statistics Committee and Stroke Statistics Subcommittee, Heart disease and stroke statistics - 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 119:480-486
22. Meller R, Stevens SL, Minami M, Cameron JA, King S, Rosenzweig H, Doyle K, Lessov NS, Simon RP, Stenzel-Poore MP (2005) Neuroprotection by osteopontin in stroke. J Cereb Blood Flow Metab 25:217-225 (Pubitemid 40171203)
23. Momiyama Y, Ohmori R, Fayad ZA, Kihara T, Tanaka N, Kato R, Taniguchi H, Nagata M, Nakamura H, Ohsuzu F (2010) Associations between plasma osteopontin levels and the severities of coronary and aortic atherosclerosis. Atherosclerosis (Epub ahead of print)
24. Montaner J, Fernandez-Cadenas I, Molina CA, Ribó M, Huertas R, Rosell A, Penalba A, Ortega L, Chacón P, Alvarez-Sabín J (2006) Poststroke C-reactive protein is a powerful prognostic tool among candidates for thrombolysis. Stroke 37:1205-1210 (Pubitemid 43731863)
25. O'Regan AW, Hayden JM, Berman JS (2000) Osteopontin augments CD3-mediated interferon-gamma and CD40 ligand expression by T cells, which results in IL-12 production from peripheral blood mononuclear cells. J Leukoc Biol 68:495-502
26. Ohmori R, Momiyama Y, Taniguchi H, Takahashi R, Kusuhara M, Nakamura H, Ohsuzu F (2003) Plasma osteopontin levels are associated with the presence and extent of coronary artery disease. Atherosclerosis 170:333-337 (Pubitemid 37377807)
27. Pessin M, del Zoppo G, Estol C (1990) Thrombolytic agents in the treatment of stroke. Clin Neuropharmacol 13:271-289 (Pubitemid 20230322)
28. Scatena M, Liaw L, Giachelli CM (2007) Osteopontin: a multi-functional molecule regulating chronic inflammation and vascular disease. Arterioscler Thromb Vasc Biol 27:2302-2309 (Pubitemid 350203943)
29. Speer MY, McKee MD, Guldberg RE, Liaw L, Yang HY, Tung E, Karsenty G, Giachelli CM (2002) Inactivation of the osteopontin gene enhances vascular calcification of matrix Gla protein-deficient mice: evidence for osteopontin as an inducible inhibitor of vascular calcification in vivo. J Exp Med 196:1047-1055 (Pubitemid 35231763)
30. Takafuji V, Forgues M, Unsworth E, Goldsmith P, Wang XW (2007) An osteopontin fragment is essential for tumor cell invasion in hepatocellular carcinoma. Oncogene 26:6361-6371 (Pubitemid 47494216)
31. Zanette EM, Roberti C, Mancini G, Pozzilli C, Bragoni M, Toni D (1995) Spontaneous middle cerebral artery reperfusion in ischemic stroke: a follow-up study with transcranial Doppler. Stroke 26:430-433